These ASX 200 blue chip shares could rise 25% to 40%

Analysts are bullish on these big names. Let's see what they are recommending.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points
  • Cochlear, a leader in hearing devices, is recommended by UBS due to its dominant market share and growth potential, with a projected 30% upside as it continues to innovate and expand product offerings.
  • CSL, despite recent pressures from its Seqirus spin-off and regulatory concerns, remains a strong investment due to its robust demand and strategic investments in plasma collection and therapy development, with Morgans forecasting a nearly 40% rise.
  • REA Group, dominating Australia's online property advertising, is expanding into financial services and data products, with Bell Potter suggesting a 25% upside, benefiting from potential interest rate cuts and its strategic market positioning.

Blue chip shares are often the cornerstone of long-term portfolios. They offer stability, strong market positions, and the ability to grow earnings through multiple economic cycles.

And with recent volatility pulling several high-quality names down meaningfully, analysts see buying opportunities emerging across the ASX 200.

For example, here are three ASX 200 blue chip shares that brokers have flagged as top buys right now. They are as follows:

A young man pointing up looking amazed, indicating a surging share price movement for an ASX company

Image source: Getty Images

Cochlear Ltd (ASX: COH)

Cochlear could be an ASX 200 blue chip share to buy. It is a leader in implantable hearing devices globally. Demand for its products continues to rise as ageing populations grow and access to hearing treatments expands worldwide.

The company's ongoing investment in research and new product development has helped it maintain its dominant market share and support steady revenue growth. And with a strong balance sheet, rising volumes, and a history of delivering consistent earnings and dividends, Cochlear continues to stand out as a reliable long-term compounder.

UBS is a fan of the company and has a buy rating and a $350.00 price target on the stock. This implies around 30% upside from current levels.

CSL Ltd (ASX: CSL)

Global biotech heavyweight CSL has come under pressure in recent months, with investor sentiment dampened by the planned Seqirus spin-off, regulatory uncertainty, and a slower-than-hoped recovery in plasma margins. But despite recent share price weakness, CSL's long-term fundamentals remain strong.

CSL continues to invest in expanding its plasma collection network, developing new therapies, and strengthening its manufacturing footprint in the United States. Demand for its core plasma-derived products remains robust, and analysts expect earnings momentum to rebuild as temporary headwinds ease.

So, with its shares trading close to a 52-week low, CSL's valuation looks significantly more appealing than it has in years.

Morgans sees meaningful upside from current levels. It has a buy rating and a $249.51 price target on its shares, which suggests that they could rise almost 40%.

REA Group Ltd (ASX: REA)

Finally, REA Group could be an ASX 200 blue chip share to buy now. It dominates Australia's online property advertising market, supported by powerful pricing power, strong customer relationships, and significant digital scale.

It has also expanded beyond listings into financial services, data products, and international investments, broadening its growth runway. With more interest rate cuts potentially coming in 2026, the company's premium positioning and deep integration into the property ecosystem give it substantial leverage to any improvement in listing volumes.

Bell Potter remains bullish. It has a buy rating and $244.00 price target on its shares, implying nearly 25% upside from current levels.

Motley Fool contributor James Mickleboro has positions in CSL, Cochlear, and REA Group. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL and Cochlear. The Motley Fool Australia has recommended CSL and Cochlear. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Share Market News

Winning woman smiles and holds big cup while losing woman looks unhappy with small cup.
Share Gainers

Here are the top 10 ASX 200 shares today

Another day, another loss for investors.

Read more »

a woman in a wheelchair sits at her desk in her home with headphones on and looking at a computer screen of figures. monitoring the CBA share price
Share Market News

Top 10 ASX shares bought and sold in April

Amid the fuel crisis and fears of a recession, here are the stocks that investors traded most.

Read more »

A smiling woman holds a Facebook like sign above her head.
Broker Notes

5 ASX shares scoring upgraded ratings this week

Experts have raised their ratings on JB Hi-Fi, Beach Energy, Amcor, and others this week.

Read more »

A woman has a thoughtful look on her face as she studies a fan of Australian 20 dollar bills she is holding on one hand while he rest her other hand on her chin in thought.
Share Market News

Should I sell my Telstra shares in May?

If I owned Telstra shares, here's what I'd do next.

Read more »

Magnifying glass on a rising interest rate graph.
Share Market News

Buying ASX shares? Here's what to expect from Tuesday's RBA interest rate meeting

Leading experts sound off on the RBA’s likely next interest rate move.

Read more »

A man sitting at his dining table looks at his laptop and ponders the share price.
Broker Notes

Down 65%: Is this ASX 300 stock a cheap buy?

This stock has been sold off. Has this created a buying opportunity? Let's see what Bell Potter is saying.

Read more »

Three guys in shirts and ties give the thumbs down.
Broker Notes

5 ASX All Ords shares downgraded by brokers this week

Brokers have reduced their ratings on PLS Group, Fortescue, Webjet, and others this week.

Read more »

A man sits in contemplation on his sofa looking at his phone as though he has just heard some serious or interesting news.
Broker Notes

Does Ord Minnett rate Goodman shares as a buy, hold, or sell?

The broker has been looking at a big agreement signed this month.

Read more »